tbuckley/cabot-search huggingface dataset:
Metformin for Type 2 Diabetes
Authors: Jayshil J. Patel, Manpreet S. Mundi
Journal: JAMA (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Pathology of Vaping-Associated Lung Injury
Authors: Yasmeen M Butt, Maxwell L Smith, Henry D Tazelaar, Laszlo T Vaszar, Karen L Swanson, Matthew J Cecchini, Jennifer M Boland, Melanie C Bois, James H Boyum, Adam T Froemming, Andras Khoor, Isabel Mira-Avendano, Aiyub Patel, Brandon T Larsen
Journal: New England Journal of Medicine (2019)

Pathology of Vaping-Associated Lung Injury This letter describes findings in 17 patients with a history of vaping who had lung biopsies after presenting with symptoms and bilateral pulmonary opacit...
Abstract 11585: Vcp979, a Novel Anti-Inflammatory Agent, Treatment Improves Cardiac Function Post-Myocardial Infarction in Diabetes Mice
Authors: Bing H Wang, Tingting Xu, Li Huang, Yue Hua, Yu Cai, Henry Krum, Peter Scammells, Shenghong Ju
Journal: Circulation (2018)

Background: Inflammation is a pivotal pathophysiological response following myocardial infarction (MI) in the setting of diabetes which leads to progressive myocardium structural changes and dysfun...
A phase II open-label, multicentre study to assess the anti-tumour activity of afatinib in patients with activating epidermal growth factor receptor mutation (EGFRm) from circulating tumour DNA (CtDNA)
Authors: Y.-C. Kim, C.-K. Park, I.-J. Oh, S.Y. Lee, J.C. Lee, C.-M. Choi, S.Y. Lee, T.W. Jang
Journal: Annals of Oncology (2019)
Prospective pathological experience with research biopsies in the context of clinical trials at Vall d’Hebron Institute of Oncology
Authors: P.G. Nuciforo, J. Jimenez, R. Fasani, F. Ruiz, C. Sevillano, G. Sanchez, P. Martinez, X. Serres, C. Saura, E. Elez, E. Felip, A. Oaknin, I. Brana, E. Muñoz-Couselo, T. Macarulla Mercade, M. Alsina Maqueda, J. Carles, R. Dienstmann, J. Tabernero, E. Garralda
Journal: Annals of Oncology (2019)
STAR-PAC: Phase I clinical trial repurposing all trans retinoic acid (ATRA) as stromal targeting agent in a novel drug combination for pancreatic cancer
Authors: H.M. Kocher, B. Basu, F.E.M. Froeling, D. Sarker, S. Slater, D. Carlin, C. Coetzee, N. de Souza, M. Goulart, C. Hughes, A. Imrali, C. Lawrence, K. Mousa, B. North, A. Prendergast, R. Roberts, P. Sasieni, D. Propper
Journal: Annals of Oncology (2019)
Efficacy of adoptive therapy with tumor-infiltrating lymphocytes and recombinant interleukin-2 in advanced cutaneous melanoma: a systematic review and meta-analysis
Authors: U Dafni, O Michielin, S Martin Lluesma, Z Tsourti, V Polydoropoulou, D Karlis, M J Besser, J Haanen, I -M Svane, P S Ohashi, U S Kammula, A Orcurto, S Zimmermann, L Trueb, C A Klebanoff, M T Lotze, L E Kandalaft, G Coukos
Journal: Annals of Oncology (2019)
Abstract 11218: S1P1 Receptors Mediate Angiogenic Responses of a Novel Adenosine Analogue COA-Cl in Human Umbilical Vein Endothelial Cells (HUVEC)
Authors: Junsuke Igarashi, Yasuo Kubota, Kazuyo Shoji, Norikazu Sakakibara, Tokumi Maruyama, Maki Takata, Hiroaki Kosaka, Ryoji Konishi, Ikuko Tsukamoto
Journal: Circulation (2013)

We have recently developed a novel adenosine analogue termed COA-Cl (figure) that elicits strong angiogenic activities comparable to those by VEGF, acting through the classic MAP kinase cascade Raf...
In Vivo Assessment of Tau Deposition in Alzheimer Disease and Assessing Its Relationship to Regional Brain Glucose Metabolism and Cognition
Authors: Vivek Baghel, Madhavi Tripathi, Girish Parida, Ravikant Gupta, Saroj Yadav, Praveen Kumar, A.B. Dey, Nishikant Avinash Damle, Rajeev Kumar, Chandrasekhar Bal
Journal: Clinical Nuclear Medicine (2019)

Aim In this study, we investigated the relationship of cerebral tau deposition ( 18 F-tau-AD-ML 104 PET/CT) with glucose metabolism ( 18 F-FDG PET/CT) and cognitive function in patients with Alzheimer disease (AD). Patients and Methods Seventy subjects (Mini Mental State Examination [MMSE] score &lt;18 = 37 [AD]; MMSE score, 18–24 = 16 [early AD]) and 17 controls were included in this study. All participants underwent detailed neurological and neuropsychological evaluation, followed by 18 F-tau-AD-ML 104 and 18 F-FDG PET/CT imaging. Region-wise SUV max ratios at 50 to 60 minutes postinjection were calculated for 18 F-tau-AD-ML 104 and 18 F-FDG, using the cerebellar cortex as the reference region. Linear models were used to investigate the association of regional 18 F-tau-AD-ML 104 retention with 18 F-FDG uptake and cognition (MMSE scores). Results 18 F-Tau-AD-ML 104 retention was observed in the parietal lobe, temporal lobe, hippocampus, parahippocampus, frontal lobe, anterior and posterior cingulate, and precuneus in advanced and early AD patient as compared with normal controls with regional hypometabolism in overlapping regions on 18 F-FDG PET. Significant negative association was found between 18 F-tau-AD-ML 104 regional retention and glucose metabolism in the parietal lobe, temporal lobe, hippocampus, parahippocampus, frontal lobe, anterior and posterior cingulate, and precuneus among patients with advanced and early AD. In advanced and early AD patients, a negative association was found between 18 F-tau-AD-ML 104 regional retention (precuneus) and cognition (MMSE score), whereas a positive association was observed between 18 F-FDG regional uptake (precuneus) and cognition (MMSE score). Conclusions Tau pathology overlapped with areas of hypometabolism on FDG PET in the brains of AD patients. Tau deposition was found to have negative association with cognitive scores in these patients.
Meta-analysis of KRAS mutation as prognostic factor in patients (pts) with resection of colorectal (CRC) liver metastases: Tumour burden and Sidedness analysis
Authors: M.R. Luca, M. Angel, F. Esteso, J. Mariani, F Sanchez Loria, M. Chacon, J M Ó Connor
Journal: Annals of Oncology (2019)
Genomic alterations predict clinical response to systemic chemotherapy and immune checkpoint blockade in biliary tract cancer
Authors: M.H. Kim, J. Yoon, M. Jang, H. Kim, Y.N. Park, M.G. Lee, H.K. Hwang, C.M. Kang, W.J. Lee, B. Kang, H.C. Chung, H.J. Choi
Journal: Annals of Oncology (2019)
Ultrasensitive serum interferon-α quantification during SLE remission identifies patients at risk for relapse
Authors: Alexis Mathian, Suzanne Mouries-Martin, Karim Dorgham, Hervé Devilliers, Hans Yssel, Laura Garrido Castillo, Fleur Cohen-Aubart, Julien Haroche, Miguel Hié, Marc Pineton de Chambrun, Makoto Miyara, Micheline Pha, Flore Rozenberg, Guy Gorochov, Zahir Amoura
Journal: Annals of the Rheumatic Diseases (2019)

Maintenance of remission has become central in the management of systemic lupus erythematosus (SLE). The importance of interferon-alpha (IFN-α) in the pathogenesis of SLE notwithstanding, its expression in remission has been poorly studied as yet. To study its expression in remission and its prognostic value in the prediction of a disease relapse, serum IFN-α levels were determined using an ultrasensitive single-molecule array digital immunoassay which enables the measurement of cytokines at physiological concentrations.A total of 254 SLE patients in remission, according to the Definition of Remission in SLE classification, were included in the study. Serum IFN-α concentrations were determined at baseline and patients were followed up for 1 year. Lupus flares were defined according to the Safety of Estrogens in Lupus Erythematosus: National Assessment version of the Systemic Lupus Erythematosus Disease Activity Index Flare Index, whereas the Kaplan-Meier analysis and Cox regression analysis were used to estimate the time to relapse and to identify baseline factors associated with time to relapse, respectively.Of all patients in remission, 26% displayed abnormally high IFN-α serum levels that were associated with the presence of antibodies specific for ribonucleoprotein (RNP), double stranded (ds)DNA and Ro/SSA60, as well as young age. Importantly, elevated-baseline IFN-α serum levels and remission duration were associated in an independent fashion, with shorter time to relapse, while low serum levels of complement component 3 and anti-dsDNA Abs were not.Direct serum IFN-α assessment with highly sensitive digital immunoassay permits clinicians to identify a subgroup of SLE patients, clinically in remission, but at higher risk of relapse.
A Randomized Phase II Trial of 5-Day Versus 10-Day Schedules of Decitabine for Older Patients with Previously Untreated Acute Myeloid Leukemia
Authors: Nicholas J Short, Hagop M. Kantarjian, Guillermo Garcia-Manero, Gautam Borthakur, Tapan Kadia, Xuelin Huang, Naval Daver, Courtney D. DiNardo, Alessandra Ferrajoli, William G Wierda, Zeev Estrov, Christopher B Benton, Prithviraj Bose, Yesid Alvarado, Steven Kornblau, Maro Ohanian, Yvonne Gaisor, Mary Ann Richie, Sherry Pierce, Elias J. Jabbour, Jorge E. Cortes, Farhad Ravandi
Journal: Blood (2017)
Abstract 915: AKT inhibition sensitizes TNBC cells with acquired drug resistance to UM-164
Authors: Nathan M. Merrill, Eric J. Lachacz, Rabia A. Gilani, LiWei Bao, Zhi Fen Wu, Sofia D. Merajver, Matthew B. Soellner
Journal: Cancer Research (2018)

Abstract One of the major clinical challenges in breast cancer treatment is the rapid development of resistance to targeted therapies. In light of this, there is significant interest in identifying markers of drug resistance. In particular, markers of drug resistance are sought that can be targeted to overcome acquired drug resistance. To this end, we have used reverse phase protein array (RPPA) analysis to identify differences in protein expression levels between cell lines that are sensitive or have acquired resistance to UM-164, a mechanistically novel, dual c-Src/p38 kinase inhibitor with potent anti-TNBC activity. UM-164 resistant cells acquire increased resistance also to many diverse chemotherapeutics and targeted agents relative to their drug-sensitive counterparts. We analyzed RPPA data for both UM0164-sensitive and UM-164-resistant cells and identified an increase in phospho-AKT, phospho-ERK, and phospho-FAK levels in the resistant cells. Using inhibitors of each upregulated pathway, we found that combination of UM-164 with MK2206, an inhibitor of AKT, resulted in an increased sensitization of cells to treatment with UM-164. Furthermore, formal Chou-Talalay synergy analyses demonstrate that AKT inhibitors + UM-164 are effectively synergistic in reducing the proliferation of drug-resistant cells. We further evaluated this combination treatment in mice, combining UM-164 and MK2206 in a xenograft of UM-164-resistant cells, showing significant anti-tumor efficacy. Finally, we show that the combination treatment resulted in increased cell death in ex vivo cultures of patient derived TNBC materials. Together, we have demonstrated that hyperactivation of AKT leads to UM-164 resistance and AKT inhibitors can be used to re-sensitize TNBC cells to UM-164. These results demonstrate that RPPA analyses are a valuable tool for the systematic and unbiased identification of truly actionable markers of therapeutic resistance. Citation Format: Nathan M. Merrill, Eric J. Lachacz, Rabia A. Gilani, LiWei Bao, Zhi Fen Wu, Sofia D. Merajver, Matthew B. Soellner. AKT inhibition sensitizes TNBC cells with acquired drug resistance to UM-164 [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 915.
THE EFFECT OF BIRTH WEIGHT ON MORTALITY IN INFANTS WITH CRITICAL CONGENITAL HEART DISEASE
Authors: Martina Steurer, Edmund Burke, Scott Oltman, Rebecca Baer, Kelli Ryckman, Randi Paynter, Liang Liang, Molly McCarthy, Sky Feuer, Christina Chambers, Mary Norton, Shabnam Peyvandi, Anita Grady, Larry Rand, Satish Rajagopal, Laura Jelliffe-Pawlowski
Journal: Journal of the American College of Cardiology (2018)
SILVELUL project: Immunohistochemical panel analyses as potential predictive and prognostic factors in pancreatic neuroendocrine tumours (PanNET) treated with CAPTEM or everolimus
Authors: A. De Jesus-Acosta, G. Crespo Herrero, M.L. Gómez-Dorronsoro, V. Alonso, M.C. Riesco Martinez, A. Custodio, C. Lopez, M. Benavent, A. Carmona Bayonas, P. Jimenez-Fonseca, M. Llanos, B. López De San Vicente, V. Arrazubi Arrula, R. Grandez, I. González-Borja, S. Goñi, I. Arozarena, M. Baretti, A. Viudez
Journal: Annals of Oncology (2019)
External validation of a prognostic score in first-line metastastic castration-resistant prostate cancer (mCRPC)
Authors: D. Lorente, R Lozano Mejorada, G AVelasco Oria De de Rueda, A Sanchez Hernandez, M Rodrigo Aliaga, Á Sánchez Iglesias, M de Julián Campayo, F Lopez Campos, N Romero Laorden, E. Castro, D Olmos Hidalgo
Journal: Annals of Oncology (2019)
Acne in the 21st century
Authors: M.A.M. Steensel
Journal: British Journal of Dermatology (2019)

Linked Articles: Clayton et al. Br J Dermatol 2019; 181:677–690. Common et al. Br J Dermatol 2019; 181:665–676. Ramasamy et al. Br J Dermatol 2019; 181:691–699. Thiboutot et al. Br J Dermatol 2019; 181:700–706.
Precision oncology in sarcoma drug development: Impact of genomic matching on response, clinical benefit, and survival in sarcoma patients on phase 1 trials.
Authors: Shiraj Sen, Roberto Pestana, Kenneth R. Hess, David S. Hong, Filip Janku, Aung Naing, Gerald Steven Falchook, Anthony Paul Conley, Shreyaskumar Patel, Funda Meric-Bernstam, Vivek Subbiah
Journal: Journal of Clinical Oncology (2019)

11018 Background: Genomic analyses have revealed many potentially actionable mutations across sarcoma subtypes. Whether sarcoma patients enrolled on genomically matched early phase trials have improved clinical outcomes over patients enrolled on non-genomically matched trials remains unclear. Methods: We analyzed clinical and next gen sequencing data from sarcoma patients on phase 1 trials at MD Anderson Cancer Center (MDACC) and performed logistic and Cox proportional hazards regression analyses to compare response rate (RR), median time to progression (mTTP), clinical benefit rate (CBR = CR, PR, or SD &gt; 6 months), and median overall survival (mOS) between patients treated on genomically-matched and non-genomically matched trials. Results: Among the 406 patients with advanced sarcomas (321 soft tissue sarcoma [STS], 85 bone sarcomas) treated on phase 1 trials at MDACC from May 2006 to May 2018, median age was 53 (range 11-84), 48% were female, and patients had a median 3 prior lines of therapy (range 0-9). The most commonly treated STS subtypes were leiomyosarcoma (n = 66; 16%), liposarcoma (n = 52; 13%), GIST (n = 44; 11%), and synovial sarcoma (n = 11; 3%) and most commonly treated bone sarcomas were osteosarcoma (n = 34; 8%), chondrosarcoma (n = 28; 7%), and Ewing's sarcoma (n = 25; 6%). 23% (n = 93) of sarcoma patients treated on phase 1 trials were treated on genomically-matched trials. RR on non-genomically matched trials was 6% compared to 11% on genomically-matched trials, OR 1.97 (95% CI 0.88, 4.44), p = 0.10. Responses on genomically-matched trials were seen with novel agents targeting TRK, LRRC15, cMET, mTOR, VEGF, MDM2, KIT/PDGFRA, and FGFR. mTTP on non-genomically matched trials was 2.7 months compared to 3.7 months on genomically-matched trials, HR 0.72 (95% CI 0.57, 0.91), p = 0.0048. CBR on non-genomically matched trials was 19% compared to 41% on genomically-matched trials, OR 2.91 (95% CI 1.77, 4.80), p &lt; 0.0001. mOS on non-genomically matched trials was 15.5 months compared to 22.1 months on genomically-matched trials, HR 0.70 (95% CI 0.50,0.98), p = 0.031. Conclusions: Enrollment on genomically-matched phase 1 trials is associated with an improvement in clinical benefit rate, time to progression, and overall survival in heavily pretreated, metastatic sarcoma patients. While RR remained low, we report the mutations associated with responses on genomically-matched trials. A prospective, biomarker-driven genomically-matched basket trial for these alterations is warranted in advanced sarcomas.
Publisher Correction: A neural circuit for comorbid depressive symptoms in chronic pain
Authors: Wenjie Zhou, Yan Jin, Qian Meng, Xia Zhu, Tongjian Bai, Yanghua Tian, Yu Mao, Likui Wang, Wen Xie, Hui Zhong, Na Zhang, Min-Hua Luo, Wenjuan Tao, Haitao Wang, Jie Li, Juan Li, Ben-Sheng Qiu, Jiang-Ning Zhou, Xiangyao Li, Han Xu, Kai Wang, Xiaochu Zhang, Yong Liu, Gal Richter-Levin, Lin Xu, Zhi Zhang
Journal: Nature Neuroscience (2019)
Longitudinal circulating tumour DNA (ctDNA) monitoring for early detection of disease progression and resistance in advanced NSCLC in FLAURA
Authors: J.E. Gray, N. Peled, A. Markovets, N. Nogami, J.-S. Lee, B.C. Cho, B. Chewaskulyong, M. Majem, T. Reungwetwattana, K. Vishwanathan, A. Todd, Y. Rukazenkov, M. Johnson, C. Barrett, J. Chmielecki, R. Hartmaier, S.S. Ramalingam
Journal: Annals of Oncology (2019)
Association of SCFA in gut microbiome and clinical response in solid cancer patients treated with andi-PD-1 antibody
Authors: M. Nomura, R. Nagatomo, K. Inoue, K. Doi, J. Shimizu, K. Baba, T. Saito, S. Matsumoto, M. Muto
Journal: Annals of Oncology (2019)
Deciphering Brain Complexity using Single-Cell Sequencing
Authors: Quanhua Mu, Yiyun Chen, Jiguang Wang
Journal: Genomics Proteomics & Bioinformatics (2019)

The human brain contains billions of highly differentiated and interconnected cells that form intricate neural networks and collectively control the physical activities and high-level cognitive functions, such as memory, decision-making, and social behavior. Big data is required to decipher the complexity of cell types, as well as connectivity and functions of the brain. The newly developed single-cell sequencing technology, which provides a comprehensive landscape of brain cell type diversity by profiling the transcriptome, genome, and/or epigenome of individual cells, has contributed substantially to revealing the complexity and dynamics of the brain and providing new insights into brain development and brain-related disorders. In this review, we first introduce the progresses in both experimental and computational methods of single-cell sequencing technology. Applications of single-cell sequencing-based technologies in brain research, including cell type classification, brain development, and brain disease mechanisms, are then elucidated by representative studies. Lastly, we provided our perspectives into the challenges and future developments in the field of single-cell sequencing. In summary, this mini review aims to provide an overview of how big data generated from single-cell sequencing have empowered the advancements in neuroscience and shed light on the complex problems in understanding brain functions and diseases.
FUS-mediated regulation of acetylcholine receptor transcription at neuromuscular junctions is compromised in amyotrophic lateral sclerosis
Authors: Gina Picchiarelli, Maria Demestre, Amila Zuko, Marije Been, Julia Higelin, Stéphane Dieterlé, Marc-Antoine Goy, Moushami Mallik, Chantal Sellier, Jelena Scekic-Zahirovic, Li Zhang, Angela Rosenbohm, Céline Sijlmans, Amr Aly, Sina Mersmann, Inmaculada Sanjuan-Ruiz, Annemarie Hübers, Nadia Messaddeq, Marina Wagner, Nick van Bakel, Anne-Laurence Boutillier, Albert Ludolph, Clotilde Lagier-Tourenne, Tobias M. Boeckers, Luc Dupuis, Erik Storkebaum
Journal: Nature Neuroscience (2019)
PD-L1 expression, patterns of progression and patient-reported outcomes (PROs) with durvalumab plus platinum-etoposide in ES-SCLC: Results from CASPIAN
Authors: L. Paz-Ares, J.W. Goldman, M.C. Garassino, M. Dvorkin, D. Trukhin, G. Statsenko, K. Hotta, J.H. Ji, M.J. Hochmair, O. Voitko, L. Havel, A. Poltoratskiy, G. Losonczy, N. Reinmuth, Y. Shrestha, N. Patel, H. Mann, H. Jiang, M. Özgüroğlu, Y. Chen
Journal: Annals of Oncology (2019)
A phase I study of amrubicin (AMR) and cyclophosphamide in patients with advanced solid organ malignancies: Correlative analysis of a trial from the Hoosier Oncology Group.
Authors: C. Albany, S. I. Jalal, J. Turchi, J. Wu, Z. Yu, L. H. Einhorn
Journal: Journal of Clinical Oncology (2011)

e17517 Background: AMR is an anthracycline with activity against small cell lung cancer (SCLC). Amrubicinol (AMR-OH) is an active metabolite of AMR. NAD(P)H quinone oxidoreductase 1(NQO1) participates in the metabolism of AMR and AMR-OH. NQO1 single nucleotide polymorphisms (SNPs) have been suggested as a contributing factor to AMR efficacy in Japanese patients (pts). We therefore analyzed NQO1 polymorphisms from a phase I study evaluating the combination of AMR and cyclophosphamide and their correlation with response and toxicity. Methods: Blood samples were collected from pts prior to therapy. Genomic DNA was extracted and genotyping conducted for the C to T point mutation at base pair 609 of exon 6, which codes for a proline to serine substitution in NQO1 protein. Results: Genotyping data was available for all 36 pts; CC genotype (normal enzyme activity) was detected in 23 pts (64%), CT genotype (reduced enzyme activity) in 13 pts (36%). TT genotype (associated with loss of NQO1 activity) was not detected in our pt population. Response data was available for 34 pts. No significant association (or correlation) between CC or CT polymorphisms and response or ≥ grade 4 toxicity was noted at 95% confidence level (p > 0.05). Conclusions: No correlation was noted in our study between NQO1 polymorphisms and response or toxicity to AMR. Exploratory objectives of the phase I study also include analysis of topoisomerase IIA amplifications by FISH and correlation with response to AMR. These studies are currently underway and will be presented at the ASCO Meeting.
Immune-Related Adverse Events of Immune Checkpoint Inhibitors—From a Clinical to Pathophysiological View
Authors: Xu Yang, Jianzhen Lin, Haitao Zhao
Journal: JAMA Oncology (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal